Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

June 8, 2022 BIZ PEOPLE

GNHCC promotes Benowitz to workforce, economic development role

Photo | Contributed Anne Benowitz

Anne Benowitz has a new leadership role within the Greater New Haven Chamber of Commerce.

Benowitz has been promoted to vice president of economic development and workforce initiatives. She previously served as director of economic development.

Benowitz is responsible for regional business retention and expansion efforts. She will also focus on making connections and providing resources needed to retain and expand businesses in Connecticut. Her job also entails the development of talent pipelines through regional partnerships.

Garrett Sheehan, president and CEO of the chamber, said Benowitz has “done a great job” building its economic development program and spearheading the growth of its workforce development programs.

“Seeing as the workforce is a top area of concern to our business community, this is a chamber priority, and this expanded role will also allow us to better serve the business community,”  Sheehan said. 

Rallybio announces planned retirement of CFO

Rallybio Corporation, a New Haven-based clinical-stage biotechnology company, recently announced that Jeffrey Fryer will retire from his position as chief financial officer.

Fryer, a company co-founder, will continue to serve in the role until a new CFO has been appointed and during a transition period. Rallybio has begun searching externally for a new CFO.

CEO Martin Mackay thanked Fryer for his contributions in the past four years in creating and building Rallybio into a publicly-traded company. 

“With a growing pipeline and our strong financial position, I believe that now is the right time for me to retire from the company and to pursue a few other ambitions,” Fryer said. “I am fully committed to ensuring a smooth transition and look forward to following the continued success of the Rallybio team.”

Rallybio, launched in 2018, has built a portfolio of product candidates now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal-fetal health and metabolic disorders.

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF